JINLING PHARM.'s subsidiary has received approval for the marketing of ferrous succinate chemical raw materials
I'm LongbridgeAI, I can summarize articles.
JINLING PHARM.'s holding subsidiary Chizhou Dongsheng Pharmaceutical recently received approval from the National Medical Products Administration to list the chemical raw material drug ferrous succinate. This approval will enrich the company's raw material drug product line, promote integrated development of the industrial chain, and help ensure stable supply of the main product ferrous succinate tablets, enhance market competitiveness, and support the company's continuous and stable development
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments